Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly

American Journal of Health-System Pharmacy

Volumn 64, Issue 2 SUPPL., 2007, Pages

  Beier, Manju T ^a,b  

^a Geriatric Consultant Resources LLC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antipsychotic agents; Dementia; Diagnosis; Drug interactions; Drugs; Geriatrics; Mechanism of action; Toxicity

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; APATHY; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DELUSION; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE INTOLERANCE; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IRRITABILITY; METABOLIC DISORDER; MORTALITY; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 33947520357     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060594     Document Type: Conference Paper

References (53)

1. Torti FM Jr., Gwyther LP, Reed SD et al. A multinational review of recent trends and reports in dementia caregiver burden. Alzheimer Dis Assoc Disord. 2004; 18:99-109.
2. O'Donnell BF, Drachman DA, Barnes HJ et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992; 5:45-52.
3. Scarmeas N, Brandt J, Albert M et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005; 62:1601-8.
4. Lyketsos CG, Steele C, Baker L et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci. 1997; 9:556-61.
5. Gonzalez-Salvador T, Lyketsos CG, Baker A et al. Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry. 2000; 15:181-9.
6. Alexopoulos GS, Streim J, Carpenter D et al. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004; 65(Suppl 2):5-19.
7. Alexopoulos GS, Chung H, Jeste DV. Treatment of dementia and its behavioral disturbances. The Expert Consensus Guideline Series. 2005.
8. International Psychogeriatric Association. Behavioral and psychological symptoms of dementia educational pack. International Psychogeriatric Association. www.ipa-online.org/ipaonlinev3/ipaprograms/bpsdarchives/bpsdrev/ toc.asp (accessed 28 February 2006).
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - text revision. 4th ed. Arlington, VA: American Psychiatric Association; 2000.
10. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000; 8:29-34.
11. Olin JT, Katz IR, Meyers BS et al. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and back ground. Am J Geriatr Psychiatry. 2002; 10:129-41.
12. Lyketsos CG, Steinberg M, Tschanz JT et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000; 157:708-14.
13. Paulsen JS, Salmon DP, Thal LJ et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000; 54:1965-71.
14. Ballard CG, Margallo-Lana M, Fossey J et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry. 2001; 62:631-6.
15. Leroi I, Voulgari A, Breitner JC et al. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry. 2003; 11:83-91.
16. Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry. 1999; 60(Suppl 8):11-20.
17. Zayas EM, Grossberg GT. Treating the agitated Alzheimer patient. J Clin Psychiatry. 1996; 57(Suppl 7):46-51.
18. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001; 9:361-81.
19. Lawlor BA. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry. 2004; 65(Suppl 11):5-10.
20. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005; 293:596-608.
21. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553-63.
22. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006; 14:191-210.
23. Schneider LS, Tariot PN, Lyketsos CG et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9:346-60.
24. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006; 355:1525-38.
25. Katz IR, Jeste DV, Mintzer JE et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107-15.
26. Brodaty H, Ames D, Snowdon J et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64:134-43.
27. Street JS, Clark WS, Gannon KS et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000; 57:968-76.
28. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999; 60:292-8.
29. Yang CH, Tsai SI, Hwang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis. J Psychopharmacol.2005; 19:661-6.
30. Ballard C, Margallo-Lana M, Juszczak E et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005; 330:874.
31. Tariot PN, Schneider L, Katz IR et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006; 14:767-76.
32. Rocha FL, Hara C, Ramos MG et al. An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. Dement Geriatr Cogn Disord. 2006; 22:445-8.
33. De DP, Jeste DV, Swanink R et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005; 25:463-7.
34. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry. 2004; 65(Suppl 11):11-15.
35. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry. 1999; 60(Suppl 8):29-41.
36. Saltz BL, Woerner MG, Kane JM et al. Prospective study of tardive dyskinesia incidence in the elderlv. JAMA. 1991; 266:2402-6.
37. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004; 6(Suppl 2):3-7.
38. De Deyn P, Jeste D, Auby P et al. Aripiprazole in dementia of the Alzheimer's type. Presented at the 16th Annual Meeting of AAGP. Honolulu, HI; March 2003.
39. Dekker JM, Girman C, Rhodes T et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112:666-73.
40. Hanley AJ, Karter AJ, Williams K et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation. 2005; 112:3713-21.
41. Health Canada. Risperdal® (risperdone) and cerebrovascular adverse events in placebo-controlled dementia trials. www.hc-sc.gc.ca/dhp-mps/medeff/ advisoriesavis/prof/2002/risperdal_hpc-cps_e.html (accessed 13 November 2006).
42. Health Canada. Zyprexa® (olanzapine) and cerebrovascular adverse events in placebo-controlled elderly dementia trials. www.hc-sc.gc.ca/dhp-mps/ medeff/advisories-avis/prof/2004/zyprexa_hpc-cps_e.html (accessed 13 November 2006).
43. Schneider, LS. Cerebrovascular adverse events and quetiapine: a pooled analysis in elderly patients with dementia. Presented at 18th Annual Meeting of the American Academy of Geriatric Psychiatry. San Diego, CA; March 2005.
44. Breder C, Kostic D, Forbes A et al. Overall safety of aripiprazole in trials of patients with psychosis of Alzheimer's dementia. [M], Poster presented at APA Annual Meeting. Atlanta, GA; 2005 May.
45. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-43.
46. FDA. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2006. Bethesda, MD.
47. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005; 353:2335-41.
48. American Association for Geriatric Psychiatry. AAGP position statement: principles of care for patients with dementia resulting from Alzheimers disease. 2006.
49. Consensus statement on improving the quality of mental health care in U.S. nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc. 2003; 51:1287-98.
50. International Psychogeriatric Association. Behavioral and psychological symptoms of dementia educational pack. www.ipa-online.org/ipaonlinev3/ ipaprograms/bpsdarchives/bpsdrev/toc.asp (accessed 21 November 2006).
51. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56:1154-66.
52. Tariot PN. An overview of main outcomes in CATIE-AD. Presented at: American Psychiatric Association 2005. 2005.
53. Rabins PV, Lyketsos CG. Antipsychotic drugs in dementia: what should be made of the risks? JAMA. 2005; 294:1963-5.